Exchange: NYSE·Updated 07:59 PM EDT
News
all
press releases
AbbVie Seeks EU Nod for Subcutaneous Skyrizi in Crohn's Disease
ABBV seeks EU approval for a subcutaneous Skyrizi induction option in Crohn's disease, potentially adding convenience for patients.
Zacks
More News
FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now
FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.
Zacks
AbbVie Submits Regulatory Application to EMA for SKYRIZI (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
AbbVie Submits Regulatory Application to EMA for SKYRIZI (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease AbbVie Submits Regulatory Application to EMA for SKYRIZI (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active...
PR Newswire
If You Invested $100 In AbbVie Stock 10 Years Ago, You Would Have This Much Today
AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.74% on an annualized basis producing an average annual return of 15.14%. Currently, AbbVie has a market capitalization of $468.74 billion.read more...
Benzinga
Billionaire Ken Griffin Increased His Stake in This Dividend King by 547% in Q2. Wall Street Thinks It's Still a Buy.
Key PointsThe hedge fund manager bought some 2.7 million shares of AbbVie stock in the second quarter...
Nasdaq News: Markets
How Did ABBV's Oncology Sales Hold Up in Q2 Amid Imbruvica Headwinds?
AbbVie's oncology sales fall 2.4% in Q2 as Imbruvica declines, while Venclexta and newer drugs help offset the pressure.
Zacks
LLY vs. ABBV: Which Stock Has the Stronger Growth Prospects?
Lilly and AbbVie bring different growth drivers, pipelines and risks to the table. See which drugmaker offers the more compelling 2026 upside.
Zacks
RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy
REGENXBIO stock plunges 25% after the FDA places a clinical hold on RGX-121 for MPS II, following asymptomatic spine MRI findings in five participants.
Zacks
Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk?
Spyre has a broad clinical pipeline and cash runway, but elevated valuation makes upcoming readouts critical to its investment case.
Zacks
Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?
SYRE expands into HS with SPY772, testing whether dual-pathway inhibition can strengthen outcomes in SKYLIGHT.
Zacks

Advertisement|Remove ads.